Aarey Drugs & Pharmaceuticals balance sheet

As of Mar 2026

Total assets: ₹297cr+24.8% on Mar 2025
Shareholders' equity: ₹150cr+8.6% on Mar 2025
Total debt: ₹50.0cr+43.3% on Mar 2025
Cash and investments: ₹1.4cr−5.1% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	25.8	16.2	14.7	13.9
	0.0	2.1	1.4	0.4
	2.1	0.0	0.0	0.0
	6.4	1.0	0.7	0.8
	0.0	0.0	184	0.0
	—	5.7	5.7	0.0
	8.5	6.6	191	0.8
	—	0.0	—	5.6
	34.3	25.0	207	20.7
	41.5	45.5	34.7	28.8
	130	130	0.0	190
	1.4	1.5	1.6	0.7
	20.6	29.9	15.5	9.0
	69.7	1.8	46.3	0.4
	221	163	63.4	200
	—	5.0	0.0	41.9
	263	213	98.1	271
	297	238	305	291
Equity
	28.5	28.1	28.1	25.4
	122	110	105	92.0
	150	138	133	117
	150	138	133	117
Liabilities
	1.0	2.0	3.2	4.4
	1.0	2.0	3.2	4.4
	0.8	0.9	0.7	1.4
	1.7	2.9	4.0	5.8
	49.0	32.9	28.1	33.4
	81.6	54.1	129	127
	10.8	0.0	0.0	0.0
	141	87.0	157	161
	2.1	2.7	4.4	3.5
	1.6	1.4	1.3	1.8
	—	5.7	5.4	2.2
	145	96.9	168	168
	147	99.8	172	174
	297	238	305	291
Trade payables — MSME split
	81.6	54.1	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AAREYDRUGS₹108.05

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersNECLIFE NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹307 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	13.9	14.7	16.2	25.8	25.8
+ Investment Property	0.4	1.4	2.1	0.0	0.0
+ Non-current Investments	0.0	0.0	0.0	2.1	2.1
+ Long-term Loans	0.8	0.7	1.0	6.4	6.4
+ Trade Receivables — Non-current	0.0	184.5	0.0	0.0	0.0
+ Other Non-current Financial Assets	0.0	5.7	5.7	—	—
Non-current Financial Assets	0.8	190.8	6.6	8.5	8.5
+ Other Non-current Assets	5.6	—	0.0	—	—
Total Non-current Assets	20.7	206.9	25.0	34.3	34.3
Current Assets
+ Inventories	28.8	34.7	45.5	41.5	41.5
+ Trade Receivables	189.8	0.0	129.6	129.7	129.7
+ Cash & Cash Equivalents	0.7	1.6	1.5	1.4	1.4
+ Short-term Loans	9.0	15.5	29.9	20.6	20.6
+ Other Current Financial Assets	0.4	46.3	1.8	69.7	69.7
Current Financial Assets	199.9	63.4	162.8	221.4	221.4
+ Other Current Assets	41.9	0.0	5.0	—	—
Total Current Assets	270.6	98.1	213.3	262.9	262.9
Total Assets	291.3	305.0	238.3	297.2	297.2
Equity
+ Equity Share Capital	25.4	28.1	28.1	28.5	28.5
+ Other Equity / Reserves	92.0	104.7	110.4	122.0	122.0
Equity — Owners of Parent	117.4	132.8	138.5	150.4	150.4
Total Equity	117.4	132.8	138.5	150.4	150.4
Liabilities
+ Borrowings — Non-current	4.4	3.2	2.0	1.0	1.0
Non-current Financial Liabilities	4.4	3.2	2.0	1.0	1.0
+ Deferred Tax Liabilities	1.4	0.7	0.9	0.8	0.8
Non-current Liabilities	5.8	4.0	2.9	1.7	1.7
+ Borrowings — Current	33.4	28.1	32.9	49.0	49.0
+ Trade Payables	127.3	128.9	54.1	81.6	81.6
+ Other Current Financial Liab	0.0	0.0	0.0	10.8	10.8
Current Financial Liabilities	160.7	157.1	87.0	141.4	141.4
+ Provisions — Current	3.5	4.4	2.7	2.1	2.1
+ Current Tax Liabilities	1.8	1.3	1.4	1.6	1.6
+ Other Current Liabilities	2.2	5.4	5.7	—	—
Current Liabilities	168.1	168.2	96.9	145.1	145.1
Total Liabilities	173.9	172.2	99.8	146.8	146.8
Total Equity & Liabilities	291.3	305.0	238.3	297.2	297.2
Trade Payables — MSME split
+ Dues to Other Creditors — Current	—	—	54.1	81.6	81.6
Regulatory Disclosures — filed alongside, not part of the B/S
+ Original Allocation	—	—	—	—	31.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.